#Avastin (Ovarian Cancer) Market Research Report

[markettrendus]

Global Avastin (Ovarian Cancer) Market Analysis, Company Profiles, Industry Development Strategies To 2029

Global Avastin (Ovarian Cancer) Market Analysis, Company Profiles, Industry Development Strategies To 2029

Global Avastin (Ovarian Cancer) Market Growth 2022-2029 by Market.biz presents a comprehensive picture of this market from a worldwide viewpoint. End-users can benefit from this complete market research report with all the required useful information about this market. The Global Avastin (Ovarian Cancer) report covers a descriptive analysis with detailed segmentation, complete research and…

[marketresearchtrendsblog]

Monoclonal Antibodies Market: Revenue Growth, Key Players, Qualitative Analysis, Forecast 2020-2028

The monoclonal antibody market is estimated to represent a global market of USD 135.6 billion by 2025 with growth rate of 4.8%. Biologics industry has been constantly on rise which strongly support the growth of monoclonal antibody market. Due to this fact, the utilization of monoclonal antibody has increased over the past few years owing to the increased awareness of these therapeutics among physicians and patients.For example, in 2012, approximately 20% of the total pharmaceutical revenue generated from biologic products and is anticipated to increase around 25% by the end of 2018. Furthermore, successful commercialization of monoclonal antibodies like Avastin, Rituxan and Remicade further boosted the customer base. For example, mAbs such as Avastin clocked more than US$ 6 billion of sale across the globe in 2013. Increasing uptake of these therapeutics support the market development. The market covers the analysis of the commercial or pipeline monoclonal antibody therapeutics such as Humira (adalimumab, anti-TNF), Enbrel, Remicade, Rituxan, Avastin, Herceptin, Lucentis, Erbitux, Eylea and many others.The global market is categorized in terms of source, end use and diseases. Based on source, the market is divided in murine, chimeric, humanized and human. Humanized and human segments are accounted for the largest share of the global market. Reason behind the high growth of this segments as these are considered as a natural drug and offers good safety on in vivo use.Synagis, Herceptin, Zenapax, Myelotarg, Campath, Xolair, Raptiva, Avastin, Tsyabri, Humira, Vectibix , and Cosentyx are some of the examples of human or humanized monoclonal antibodies. In terms of diseases, the market is segmented as autoimmune diseases, Inflammatory diseases, Infectious diseases and others. The utilization of monoclonal antibody therapeutics in cancer treatments and autoimmune diseases is whooping the market growth. Continuous rise in the incidence rate of cancer and autoimmune diseases along with growing demand for effective therapeutics in these area drive the market growth to great extent. End user segment is divided as hospitals, research laboratories and others. Hospitals segment dominated the market, captured almost 41.23% share of the global market in 2016.

Request to Fill The Form To get Sample Copy of This Report: https://www.sdki.jp/sample-request-53378 Regionally, developed regions such as North America and Europe are considered to be the largest market. Of which, North America accounted for almost 50% share of the global market in 2016. Increasing number of research and development activities coupled with rise in awareness among end users about monoclonal antibody drives the market growth. U.S. based Pfizer, Inc. is currently researching on avelumab—monoclonal antibody for indications such as non-small cell lung cancer, ovarian cancer, and others. These companies spenda significant share of their revenue on research activities, to develop novel mAbs. Europe is also considered to capture significant market share, 25% global share in 2016. Increasing approval of novel monoclonal antibodies is expected to stimulate the market demand. In 2012, European Medicines Agency (EMA) released guidelines on biosimilar mAb development. This guideline demonstrates the capability of biosimilar mAbs with an interest in development of similar biological mAbs, leading to drive market growth. Asia Pacific and Latin American countries are projected to grow with the promising growth rate during the future period. Companies such as F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc, Novartis AG; Pfizer; Shanghai Junshi Bioscience Co., Ltd, Daiichi Sankyo Company, Ltd., and others are operating in this market. These companies are engaged in strategic merger and acquisitions to expand their market share in this market. For example, Roche, Inc. acquired California based Genentech which has helped company to expand its market share in monoclonal antibody segment. Aside from Roche, Abbott Laboratories also exhibit strong potential in the monoclonal antibody sector. Growth of this company is attributed to its acquisition of Knoll Pharmaceutical Co. unit and licensing rights to MedImmune’s Synagis and Numax. Further, Johnson & Johnson enhance its market presence supported by the strong growth of Stelara (ustekinumab), Simponi (golimumab), and bapineuzumab. The market size and forecast for each segment has been provided for the period 2014 to 2025, considering 2015 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2016 to 2025 for every reported segment. The years considered for the study are: Historical Year – 2014 & 2015 Base Year – 2015 Estimated Year – 2016 Projected Year – 2025 TARGET AUDIENCE Traders, Distributors, And Suppliers Hospitals Manufacturers Government and Regional Agencies and Research Organizations Consultants Distributors

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows: MARKET, BY SOURCE Murine Chimeric Humanized Human MARKET, BY DISEASE Autoimmune diseases Inflammatory diseases Infectious diseases others MARKET, BY END USE Hospitals Research labs Others MARKET, BY REGION North America Europe Asia Pacific Rest of the World MARKET, BY COUNTRY Further Breakdown of The North America Market U.S. Canada Further Breakdown of The Europe Market Germany France Rest of Europe Further Breakdown of The APAC Market India China Rest of APAC Further Breakdown of The Rest of the World Market Middle-East and Africa Latin America

The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.

[kunalcmi]

INDIA IMMUNE-ONCOLOGY DRUGS MARKET ANALYSIS  - (2018-2026)

Immuno-Oncology refers to the use of body’s natural defenses to fight disease. It works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in functionality of healthy cells. Immuno-oncology drugs facilitates long-term response against cancer by providing long-lasting memory to the immune system. Immuno-Oncology drugs works against a wide variety of cancers, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others. Immuno-oncology uses different types of cell-based immune therapies such as monoclonal antibodies, immune checkpoint inhibitors, cytokine-based immunotherapy, cancer vaccines, and other therapies. Commercially available immune-oncology therapies include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

Market Dynamics

Increasing prevalence of cancer in India is expected to drive India Immune-Oncology Drugs Market growth. For instance, according to National Cancer Registry Programme (NCRP), India, one woman dies of cervical cancer every 8 minutes in India. For every 2 women newly diagnosed with breast cancer, one woman dies of it in India. Furthermore, as many as 2,500 persons die every day due to tobacco-related diseases in India. Tobacco (smoked and smokeless) use accounted for around 317,928 deaths in men and women in 2018.

However, factors such as high-cost associated with immuno-oncology therapies makes it unaffordable for population in the low and middle-income class, to opt for these therapies, thus restraining growth of the market. For instance, Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer costs around US$ 2,250 for a vial of 50 mg. Moreover, according to the World Health Organization (WHO), in February 2018, around 70% of deaths from cancer occur in low and middle-income countries. This can be attributed to high-prices of oncology therapies, which cannot be afforded by patients with low incomes.

Request Sample Free Copy of Report here: https://www.coherentmarketinsights.com/insight/request-sample/2631

Download PDF Brochure:https://www.coherentmarketinsights.com/insight/request-pdf/2631

Key features of the study:

This report provides in-depth analysis of the India Immune-Oncology Drugs Market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players

It profiles key players in the India immuno-oncology drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies

Key players covered as a part of this study include Amgen, Inc., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories, Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology company, Reliance Life Sciences, Biocon Limited and Hetero Drugs Limited.

Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics

India immuno-oncology drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for India immuno-oncology drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

India Immuno-Oncology Drugs Market, By Drug Type:

Immune Checkpoint Inhibitors

Nivolumab (Opdivo)

Atezolimumab (Tecentriq)

Pembrolizumab (Keytruda)

Durvalumab (Imfinzi)

Monoclonal Antibodies

Rituximab (Rituxan)

Trastazumab (Herceptin)

Bevacizumab (Avastin)

Nimotuzumab (Biomab EGFR)

Pertuzumab (Perjeta)

Ado-Trastuzumab Emtansine (Kadcyla)

Cancer Vaccines

Gardasil

Cervarix

India Immuno-Oncology Drugs Market, By Cancer Type:

Lung Cancer

Blood Cancer

Breast Cancer

Ovarian Cancer

Cervical Cancer

Colorectal Cancer

Stomach Cancer

Head & Neck Cancer

Others

Company Profiles

Amgen, Inc.*

Company Overview

Product Portfolio

Financial Performance

Recent Highlights

Strategies

Hoffmann-La Roche AG

Intas Pharmaceuticals Ltd.

AstraZeneca plc

Mylan N.V.

Reddy's Laboratories

Bristol - Myers Squibb

Merck & Co., Inc.

BIOCAD-Biotechnology company

Reliance Life Sciences

Biocon Limited

Hetero Drugs Limited

“*” marked represents similar segmentation in other categories in the respective section.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

Explore CMI Services here

Contact Us:

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Source: https://www.coherentmarketinsights.com/market-insight/india-immune-oncology-drugs-market-2631

[adwaitcoherent]

By 2026, India Immune-Oncology Drugs Market To Surpass US$ 461.8 Million - Coherent Market Insights

India Immune-Oncology Drugs Market To exhibit a CAGR of 13.1% over the forecast period (2018 - 2026)

Request for Sample PDF Copy:

https://www.coherentmarketinsights.com/insight/request-pdf/2631

Description:

Immuno-Oncology refers to the use of body’s natural defenses to fight disease. It works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in functionality of healthy cells. Immuno-oncology drugs facilitates long-term response against cancer by providing long-lasting memory to the immune system. Immuno-Oncology drugs works against a wide variety of cancers, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others. Immuno-oncology uses different types of cell-based immune therapies such as monoclonal antibodies, immune checkpoint inhibitors, cytokine-based immunotherapy, cancer vaccines, and other therapies. Commercially available immune-oncology therapies include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

 Market Dynamics

 Increasing prevalence of cancer in India is expected to drive India Immuno-Oncology Drugs market growth. For instance, according to National Cancer Registry Programme (NCRP), India, one woman dies of cervical cancer every 8 minutes in India. For every 2 women newly diagnosed with breast cancer, one woman dies of it in India. Furthermore, as many as 2,500 persons die every day due to tobacco-related diseases in India. Tobacco (smoked and smokeless) use accounted for around 317,928 deaths in men and women in 2018.

 However, factors such as high-cost associated with immuno-oncology therapies makes it unaffordable for population in the low and middle-income class, to opt for these therapies, thus restraining growth of the market. For instance, Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer costs around US$ 2,250 for a vial of 50 mg. Moreover, according to the World Health Organization (WHO), in February 2018, around 70% of deaths from cancer occur in low and middle-income countries. This can be attributed to high-prices of oncology therapies, which cannot be afforded by patients with low incomes.

 Key features of the study:

 This report provides in-depth analysis of the India immuno-oncology drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players

It profiles key players in the India immuno-oncology drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies

Key players covered as a part of this study include Amgen, Inc., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories, Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology company, Reliance Life Sciences, Biocon Limited and Hetero Drugs Limited.

Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics

India immuno-oncology drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for India immuno-oncology drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

 India Immuno-Oncology Drugs Market, By Drug Type:

Immune Checkpoint Inhibitors

Nivolumab (Opdivo)

Atezolimumab (Tecentriq)

Pembrolizumab (Keytruda)

Durvalumab (Imfinzi)

Monoclonal Antibodies

Rituximab (Rituxan)

Trastazumab (Herceptin)

Bevacizumab (Avastin)

Nimotuzumab (Biomab EGFR)

Pertuzumab (Perjeta)

Ado-Trastuzumab Emtansine (Kadcyla)

Cancer Vaccines

Gardasil

Cervarix

India Immuno-Oncology Drugs Market, By Cancer Type:

Lung Cancer

Blood Cancer

Breast Cancer

Ovarian Cancer

Cervical Cancer

Colorectal Cancer

Stomach Cancer

Head & Neck Cancer

Others

Company Profiles

Amgen, Inc.*

Company Overview

Product Portfolio

Financial Performance

Recent Highlights

Strategies

Hoffmann-La Roche AG

Intas Pharmaceuticals Ltd.

AstraZeneca plc

Mylan N.V.

Reddy's Laboratories

Bristol - Myers Squibb

Merck & Co., Inc.

BIOCAD-Biotechnology company

Reliance Life Sciences

Biocon Limited

Hetero Drugs Limited

“*” marked represents similar segmentation in other categories in the respective section.

About Us: Coherent Market Insights is a global market intelligence��and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We do offer wide range of services such as Industry analysis, Consulting services, Market Intelligence, Customized research services and much more. We have expertise in many fields such as healthcare, chemicals and materials, Automation, semiconductors, electronics, energy, food and beverage, packaging and many more. Visit our website to know more.

 Buy Report Here:

https://www.coherentmarketinsights.com/insight/buy-now/2631

Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave.  #3200  Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

[pharmanewstrands-blog]

Ovarian Cancer Drugs Market Pipeline Analysis 2018

Ovarian cancer is one of the most dreadful type of cancer widely found in women. In this cancer, abnormal cells growth is experienced in the ovaries, which has potential to invade or adversely affect other body parts such as abdomen layers, lining of the bowel and bladder, lymph nodes, and liver. Initial stages of ovarian cancer are associated with few vague symptoms, which further manifest as the cancer grows. These symptoms include inflating, pelvic ache, abdominal puffiness, and loss of appetite.

Request A Sample Copy: http://bit.ly/2mk94EF

Ovarian cancer is a relatively rare cancer as compared to other types, though risk is higher among women who have ovulated more over their lifetime, which can also include females who have never borne a child and those who began ovulating at a very young age. According to American Cancer Society, around 10% of ovarian cancer cases are related to inherited genetic risk. Women with mutations in BRCA1 or BRCA2 genes have 50% chance of developing breast or ovarian cancer. Ovarian carcinoma, is the most common ovarian cancer that accounts for 95% of cases, globally.

Ovarian cancer drugs market supported by growing aging population in the U.S. and U.K.

Rising number of ovarian cancer cases recorded over the recent past, is creating a highly conducive environment for growth of the ovarian cancer drugs market. According to American Cancer Society, in 2016, around 22,280 new cases of ovarian cancer were diagnosed, leading to 14,240 deaths in the U.S. According to the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute data, an increase in all new cancer cases is recorded, with ovarian cancer accounting for 1.3% of the incidence rate, and 2.4% of all related deaths, in 2016. The number of new ovarian cancer cases account for 11.9 per 100,000 women, and the total deaths account for 7.5 per 100,000 women, annually.

According to World Cancer Research Fund International data on the basis of highest rate of ovarian cancer by country: Fiji, age standardized rate per 100,000 is 14.9, followed by Latvia and Bulgaria with age standardized rate per 100,000 being 14.2 and 14.0, respectively. The U.K. stands tenth, with age standardized rate per 100,000 pegged at 11.7. Around 58% of ovarian cancer cases are diagnosed in emerging economies, with the highest incidence rate recorded in Africa and Asia Pacific. In the U.K., around 46% of women diagnosed with ovarian cancer, survive for around five years or more following the onset of the disease. According to Australian Government, Cancer Australia, as of 2017, 1,580 new ovarian cancer cases are estimated to be diagnosed, accounting for 2.5% of ovarian cancer cases among all new cancer cases in the country. This is estimated to result in 1,047 deaths in 2017. Thus, the ovarian cancer drugs industry is expected to gain significant traction in developed regions, in the near future.

Current scenario in ovarian cancer drugs market: High prevalence of ovarian cancer among women over 60 years in the U.S. and U.K.

Regional segmentation of the global ovarian cancer drugs market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America accounts for the largest market share, mainly due to presence of major players and adoption of advanced medical technologies in countries such as the U.S. and Canada.

According to American Cancer Society, most of the ovarian cancer cases are reported among women aged 60 years and above. According to Cancer Research UK, in 2014, 7,378 new cases of ovarian cancer were reported in the country, of which around 53% of cases diagnosed were among females aged 65 years and above.

Combinational drug approach, a novel approach in the ovarian cancer drugs market

Key players operating in the ovarian cancer drugs market include Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Novogen, Inc., Genentech Inc., Aetera Zenteris Inc., Boehringer Ingelheim GmbH, and F. Hoffman-La Roche Ltd. Major companies in this market are constantly working towards introducing innovative products and lowering production costs in order to enhance profitability. For instance, Roche’s blockbuster drug Avastin (bevacizumab) used in combination with carboplatin and paclitaxel is being used to treat ovarian cancer.

Key Developments

Research and development related to the diagnosis and treatment of ovarian cancer is expected to offer lucrative opportunities for market players. For instance, in August 2019, researchers from The George Washington University School of Medicine and Health Sciences, U.S. identified ovarian cancer drug resistance protein that needs to be blocked for the treatment of patients with platinum-resistant ovarian cancer.

Click To Read More On: Ovarian Cancer Drugs Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:sales@coherentmarketinsights.com

[sumit76652-blog]

Cervical Cancer Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

Cervical cancer develops in women’s cervix, and mainly affects sexually active women aged between 30 and 45. Cervical cancer often shows no symptoms in early stages. However, the death rate of cervical cancer can be significantly reduced with use of Pap test (Papanicolaou test): a screening procedure which can detect the changes in the cervix before the cancer develops. There are different types of cervical cancer, out of which two main types are squamous cell cancer and adenocarcinoma.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1746

Cervical Cancer Drugs Market Drivers

Increasing number of drug approval done by U.S. Food and Drug Administration (FDA) for the treatment of cervical cancer is expected to drive growth of the cervical cancer drugs market over the forecast period. For instance, in September 2017, U.S. Food and Drug Administration (FDA) approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer, which includes cervical, lung, brain, colorectal and kidney cancer. Mvasi is indicated for use in persistent, recurrent, or metastatic cervical cancer. In August 2014, U.S. FDA approved Genentech’s Avastin, which is bevacizumab solution for intravenous infusion in combination with paclitaxel for the treatment of persistent, recurrent, or metastatic cervical cancer.

Furthermore, increasing funding for cancer research, rising insurance coverage, and increase in the number of new targeted cancer drugs are expected to support the revenue growth of cervical cancer drugs market. For instance, National Cancer Institute, in 2015, spent around US$ 4,480 million on cancer research, which include cervical cancer, lung cancer, colorectal cancer, liver cancer, breast cancer, leukaemia, ovarian cancer, and uterine cancer. Furthermore, according to the American Cancer Society, U.S. invested around US$ 87.8 billion in 2014 on cancer research, in which the major cost accounting for around 44%, was paid by private insurance companies.

Increasing incidence of cervical cancer among the global population, rise in incidence of HIV in women, lack of awareness regarding the diagnosis for prevention of invasive cancer is expected to drive growth of the cervical cancer drugs market. Moreover, American cancer Society, in March 2018, funded around 22 grants for cervical cancer, which accounted for around US$ 9.3 million. The funding value is offered to a single or group of research, which includes a specific type of a cancer or area of cancer. For instance, according to Cancer Research UK, 2015 data findings, around 3,200 new cervical cancer cases were registered in the UK annually from 2013 to 2015.

Moreover, according to the same source, in 2015, cervical cancer accounted for around 2% of all cancer cases in females in the UK. A joint study conducted on cervical cancer by the Associated Chambers of Commerce and Industry of India (ASSOCHAM) and National Institute of Cancer Prevention and Research (NICPR), published in January 2018, reported that India alone has one fourth of the global burden of cervical cancer, which accounts for 17% of the all cancer deaths in women aged between 30 and 69 years in India. Moreover, according to the same source, it is estimated that around 1 in 53 Indian women are expected to be diagnosed by cervical cancer during their lifetime.

For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/cervical-cancer-drugs-market-1746

Cervical Cancer Drugs Market - Regional Analysis

Geographically, cervical cancer drugs market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position in cervical cancer drugs market, owing to increasing incidences of cervical cancer and growing research and development activities by various healthcare regulatory organizations in these region. For instance, according to the American Cancer Society’s (ACS) estimates for cervical cancer in the U.S. for 2018, around 13, 240 new cases of invasive cervical cancer were diagnosed and around 4,170 women are expected to die from cervical cancer. For instance, in 2013, Cervical Cancer-Free Coalition (CCFC) announced a collaborative research projects with funds ranging from US$ 5,000-US $10,000 each, which are focused on cervical cancer treatment in the U.S. 

Cervical Cancer Drugs Market Competitive Landscape

Some of the key players operating in the cervical cancer drugs market include F. Hoffmann-La Roche Ltd., Hetero, GlaxoSmithKline, plc, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Pfizer, Inc., AstraZeneca plc, Allergan plc, Biocon Limited, Bristol-Myers Squibb Company, and Novartis AG. Key players operating in the market are focused on organic growth strategies, in order to enhance its market share and retain its competence in the market. For instance, in July 2014, MedImmune: a biologics research and development division of AstraZeneca entered into a clinical trial collaboration with Advaxis. According to the agreement, both companies conducted Phase I/II immunotherapy study to evaluate the safety and efficacy of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor: MEDI4736, in combination with Advaxis’ cancer immunotherapy vaccine: ADXS-HPV. These study is conducted to develop treatment for patients with advanced, recurrent or refractory Human Papillomavirus (HPV)-associated cervical cancer.

Cervical Cancer Drugs Market Taxonomy:

By Cancer Type:

Squamous Cell Cancer

Adenocarcinoma

By Drug Type:

By Prevention

Cervarix

Gardasil 9

Recombinant Human Papillomavirus (HPV) Bivalent Vaccine

Recombinant Human Papillomavirus (HPV) Nonavalent Vaccine

Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine

Others

By Treatment

Avastin (Bevacizumab)

Bevacizumab

Bleomycin

Blenoxane (Bleomycin)

Others

By Distribution Channels:

Hospitals Pharmacies

Retail Pharmacies

Online Pharmacies

By Geography:

North America

Latin America

Europe

Asia Pacific

Middle East

Africa

Request For Customization @ https://www.coherentmarketinsights.com/insight/request-customization/1746

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

[myabhijitr]

Kidney Cancer Drugs Market Industry Growth, Outlook and Analysis by 2018-2026

The Global Kidney Cancer Drugs Market, by Therapy Class (Targeted Therapy, Immunotherapy and Chemotherapy), by Pharmacological Class (Angiogenesis Inhibitors, mTOR Inhibitors, Cytokines and Others (Immune Checkpoint Inhibitors, CTLA-4 inhibitors, Antimetabolites and Others)), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 4.6 billion in 2018, and is projected to exhibit a CAGR of 6.4% during the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.

Various key drug manufacturers are increasingly gaining regulatory drug approval for the treatment of renal cell carcinoma. These key players are launching novel and superior drug candidates in the market to capture more market share. Growing launch of innovative drugs for the treatment of renal cell carcinoma will fuel the growth of market during the forecast period.

Browse Full Report: https://www.coherentmarketinsights.com/market-insight/kidney-cancer-drugs-market-2399

For instance, in April 2018, U.S. Food and Drug Administration (FDA) approved Bristol-Myers Squibb Company’s Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg, injections for intravenous use, as the first immuno-oncology combination therapy for previously untreated patients with intermediate, and poor-risk advanced renal cell carcinoma (RCC). The combination decreased the risk of death by 37 percent compared to Sutent: a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma (RCC) and the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy.

In December 2017, the U.S. FDA granted regular approval to Exelixis, Inc.’s cabozantinib (Cabometyx) as a first line treatment for patients with advanced renal cell carcinoma (RCC). In 2016, FDA approved Cabometyx for treatment of patients with advanced RCC who received prior anti-angiogenic therapy.

Furthermore, key players are focusing on product development through strategic collaborations and commercial expansion in emerging markets. This could lead to make market more competitive, increase revenue growth of key players, and offer lucrative growth outlook during the forecast period.

Biosimilar development is gaining traction as a promising market opportunity in kidney cancer therapeutics. Several biotech companies launched Avastin biosimilars across several cancer indications in emerging markets such as India, Russia, and Argentina. For instance, in November 2017, Biocon Ltd. launched its biosimilar, bevacizumab, for the treatment of several types of cancer, under the brand name Krabeva in India, in 100 mg/4 ml vials and 400 mg/16 ml vials formulation. Krabeva is indicated as a first-line treatment for patients with metastatic colorectal cancer and used to treat lung, kidney, cervical, ovarian, and brain cancers.

Download PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2399

Key Takeaways of the Kidney Cancer Drugs Market:

The global kidney cancer drugs market is expected to exhibit a CAGR of 4% during the forecast period, owing to increasing engagement of key players in gaining drug approval and expand its market presence.

Among therapeutic class, targeted therapy segment accounted for major market share in 2017. Researchers in oncology field are focusing in the kidney cancer cells and developing newer drugs that target molecular and genetic changes. Targeted drugs are different from standard chemotherapy drugs and provide satisfactory result in kidney cancer treatment, where chemotherapy has not been shown to be very effective.

Among pharmacologic class, angiogenesis inhibitors segment accounted for the largest share in 2017. Angiogenesis inhibitor drugs play an important role in restricting the growth of cancer cells. Angiogenesis inhibitors blocks nutrients and oxygen supply to tumor in the kidney. Some of the angiogenesis inhibitors drugs used in kidney cancer treatment include Axitinib (Inlyta), Bevacizumab (Avastin), and Cabozantinib (Cometriq), among others.

Major players operating in the global kidney cancer drugs market include Pfizer Inc., Novartis International AG, Genentech, Inc., Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Eisai Co., Ltd. and Exelixis, Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702

[kunalcmi]

CANCER BIOLOGICS MARKET ANALYSIS(2020-2027)

Biologic drug is a product that contain components of living organisms such as animal, human, or produced from living organisms. Antibodies, vaccines, and interleukins are some examples of biologic drugs. Furthermore, biologic drugs are administrated by injection or infusion, as biologic products can easily lose their potency due to acid present in the stomach, if administered by oral route to the patient. Moreover, biologic drug for cancer treatment helps to increase the body’s ability to fight against various types of cancers such as nasopharyngeal cancer, prostate cancer, breast cancer, neck cancer, and lung cancer. Pembrolizumab, Atezolizumab, Cemiplimab-rwlc, Blinatumomab and Durvalumab are few examples of biologic drugs that are used for the treatment of cancer.

 Global Cancer Biologics Market Drivers

The global cancer biologics market is expected to witness significant growth over the forecast period, owing to increasing approvals of biologic drug by regulatory authorities for the treatment of cancer. For instance, in 2018, the U.S Food and Drug Administration (FDA) approved blinatumomab, for the patient suffering from B-cell precursor acute lymphoblastic leukemia, which show reduction in the severity of the disease, as the minimal residual disease (MRD) is found to be greater than or equal to 0.1%. Furthermore, in 2018, U.S FDA approved Cemiplimab-rwlc, for the treatment metastatic advanced stage cutaneous squamous cell cancer. The recommended Cemiplimab-rwlc dose for the patient is 350 mg, which is administrated as intravenous infusion over 30 minutes, in every three weeks.

Moreover, in January 2020, F. Hoffmann-La Roche AG announced about its submission of supplemental biological license to U.S Food and Drug Administration (FDA) for Tecentriq (atezolizumab), in combination with Avastin (bevacizumab) drug for most common form of liver cancer. Therefore, increasing number of regulatory approvals of biologic drug for the treatment of cancer, is expected to boost of cancer biologics market growth over the forecast period.

 Request Sample Free Copy of Report here: https://www.coherentmarketinsights.com/insight/request-sample/4145

Download PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/4145

 Global Cancer Biologics Market Restraints

However, high cost associated with cancer biologic drug is one of the major restraint that is expected to hamper the global cancer biologics market growth. For instance, cost of blinatumomab is US$ 17,800 per year. Furthermore, side effects associated with cancer biologic drug such as allergic reactions, injection site reactions, weakness, diarrhea, nausea, vomiting, and rash yet remains another factor hindering the global cancer biologics market growth.

 Global Cancer Biologics Market Regional Analysis

North America is expected to account for highest market share in the global cancer biologics market, owing to increasing prevalence of cancer, among people in North America. For instance, in 2019, in the U.S, according to the American Cancer Society’s (ACS), around 1,762,450 new cancer cases were diagnosed, and 606,880 new cancer deaths were reported.

Furthermore, increasing drug approvals for the treatment of metastatic merkel cell carcinoma (MCC) by the company is one of the factors that is driving the global cancer biologic market growth. For instance, in 2018, pembrolizumab received approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients suffering from metastatic Merkel cell carcinoma (MCC).

Europe is expected to account for second highest market share in the global cancer biologics market, owing to increasing prevalence of cancer in Europe region. For instance, in 2018, around 3.9 million of cancer with new cases excluding non-melanoma skin cancer, and 1.9 million death from cancer were reported by the International Agency for Research on Cancer (IARC), in collaboration with the European Network of Cancer Registries (ENCR, as well as the European Commission’s Joint Research Centre (JRC).

Moreover, Asia Pacific is expected to exhibit CAGR over the forecast period due to the increasing approval of drugs by regulatory bodies for the treatment of Hodgkin's disease (blood cancer) by the company. For instance, in 2018, National Medical Products Administration (NMPA) of China approved Sintilimab injection, which is sold under the brand name Tyvyt, and was jointly announced by Innovent Biologics, Inc. and Eli Lilly and Company. Sintilimab injection is used for the treatment of Hodgkin's disease (blood cancer), and is fully human IgG4 monoclonal antibody.

 Global Cancer Biologics Market Key Players

Key players operating in the global cancer biologic market are Merck & Co., Inc., Novartis International AG, F. Hoffmann-La Roche AG, Eli Lilly and Company, Bristol-Myers Squibb Company, Amgen Inc., Pfizer Inc., Sanofi S.A., Bayer AG, EnGeneIC Ltd, and GlaxoSmithKline PLC.

 Market Taxonomy:

 On the basis of product, the global cancer biologics market is segmented into:

Monoclonal Antibodies

Naked Monoclonal Antibodies

Conjugated Monoclonal Antibodies

Chemo labeled Antibodies

Radiolabeled Antibodies

Bispecific Monoclonal Antibodies

Cytokine-Based Immunotherapy

Cancer Vaccines

Treatment Vaccines

Preventive Vaccines

CAR-T Cell Therapy

Immune Checkpoint Inhibitors

CTL-4 Checkpoint Inhibitor

PD-1 & PD-L1 Checkpoint Inhibitor

On the basis of application, the global cancer biologics market is segmented into:

Non-Small Cell Lung Cancer

Prostate Cancer

Breast Cancer

Acute Myeloid Leukemia

Lymphoma

Multiple Myeloma

Ovarian Cancer

Colorectal Cancer

Gastric Cancers

Others

On the basis of distribution channel, the global cancer biologics market is segmented into:

Hospital

Clinics

Others

On the basis of region, the global cancer biologics market is segmented into:

North America

Latin America

Europe

Middle East

Asia Pacific

Africa

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

 What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

Contact Us:

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Source: https://www.coherentmarketinsights.com/ongoing-insight/cancer-biologics-market-4145

[saojip13]

Ovarian Cancer Treatment Market to 2025 Players: Eli Lilly and Company, Johnson & Johnson Services, Novogen Limited, Aeterna Zentaris and Others

Ovarian cancer is a type of cancer, which affects ovaries it causes rapid and abnormal increase of cell growth in ovaries. The exact cause of cancer is still unknown. An epithelial tumour, germ cell tumour and primary peritoneal carcinoma are types of ovarian cancer. Common symptoms include pressure in pelvis or lower back, changes in bowel movements, tiredness or low energy and more frequent urination. In most of the ovarian cancer cases, cancer will not be diagnosed until it has progressed to an advanced stage. Ovarian cancer is one of most common cause of cancer deaths in woman. Thereby need for development of the more effective drugs in treatment of ovarian cancer.

Get a Sample Copy of this Report @ https://www.alexareports.com/report-sample/170610

Increase in incidence of ovarian cancer worldwide is driving the ovarian cancer treatment market. According to WHO, an estimated 238,700 woman are diagnosed with ovarian cancer in 2012. The increase in older woman population, rising government funding and raising health care awareness able to grow ovarian cancer treatment market over the forecast period. According to ovarian cancer research fund alliance, the rate of prevalence of ovarian cancer is higher in woman between 55 to 66 years, many of the cancer foundations are funding to educate patients and healthcare professionals regarding symptoms and treatment options for ovarian cancer which may impact ovarian cancer market revenue growth positively over a forecast period. However, availability of generic drugs, lack of accurate diagnosis of ovarian cancer, and patient expiry of the key patented drugs like gemzar, taxol and paraplatin are expected to hamper the ovarian cancer treatment market.

Ovarian cancer treatment market segmented on the basis of type of cancer, drug class, and stage

Based on type of cancer, ovarian cancer treatment market is segmented into

Epithelial Ovarian Tumor Ovarian Germ Cell Tumor Ovarian Stomatal Tumor Primary Peritoneal Carcinoma

Based on drug class, ovarian cancer treatment market is segmented into

Chemotherapeutic Agents Targeted Therapy Drugs Immune System Modulators Hormones

Based on distribution channel, ovarian cancer treatment market is segmented into

Hospital Pharmacies Retail Pharmacies Others

Grab amazing discount here @ https://www.alexareports.com/check-discount/170610

Companies operating in ovarian cancer market investing in developing new drug therapies and finding newer molecular targets to treat ovarian cancer. For instance, Vintafolide an investigational targeted cancer therapeutic currently under development by Endocyte and Merck & Co. and faltetuzumab a monoclonal antibody being investigated for the treatment of ovarian cancer this was developed by Morphotek, Inc. The introduction of new drug therapies like gene therapy, radiation therapy and targeted drug therapy are projected to improve ovarian cancer market revenue growth over forecast period. Global ovarian cancer market currently dominated by generic drugs and development of more effective drugs is challenging for market players. Some of the new drugs like avastin, lynparza and yondelis are approved in recent years to treat cancer and these drugs are slowly capturing market share.

Geographically ovarian cancer treatment market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the ovarian cancer treatment market due to rising number of ageing population. According to American cancer society, in U.S. about 22,440 women will receive a new diagnosis of ovarian cancer and about 14,080 women will die from ovarian cancer in 2018. Europe is largest market as the incidence rates of ovarian cancer is increased in the region.

Some of the players in ovarian cancer treatment market include Eli Lilly and Company (U.S.), Johnson & Johnson Services, Inc. (U.S.), Novogen Limited (Australia) , Aeterna Zentaris Inc. (U.S)., GlaxoSmithKline plc (UK), Boehringer Ingelheim GmbH (Germany) and F. Hoffmann-La Roche AG (Switzerland) to name a few.

In December 2016 FDA approved rucaparib for the treatment of woman with advanced ovarian cancer who have received two or more prior chemotherapies and whose tumours have BRCA gene mutation

To Enquire About This Comprehensive Report@ https://www.alexareports.com/send-an-enquiry/170610

Report Outline:

The report provides granular level information about the market size, regional market share and forecast from 2019-2025 The report covers in-detail insights about the competitor’s overview, key findings and their key strategies The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry The report tracks recent innovations, key developments and startup’s details that are working in the industry The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

[sandlerresearch]

Ovarian Cancer: Opportunity Analysis and Forecasts to 2028 published on

http://www.sandlerresearch.org/ovarian-cancer-opportunity-analysis-and-forecasts-to-2028.html

Ovarian Cancer: Opportunity Analysis and Forecasts to 2028

Ovarian Cancer: Opportunity Analysis and Forecasts to 2028

Summary

Ovarian cancer is a rare gynecological disease that spans a broad range of genetic and histological subtypes, for which platinum-based chemotherapy has been the standard of care (SOC) for decades. Ovarian cancer can be broken down into many different types of neoplasms based on specific histopathologic entities and clinical behaviors, and treatment depends on the specific tumor type. Primary cytoreductive debulking surgery and platinum based chemotherapy form the SOC in advanced ovarian cancer. Roche’s angiogenesis inhibitor Avastin (bevacizumab) is optionally used with SOC doublet chemotherapy, particularly in patients with late stage disease. In addition to Avastin, three poly-ADP ribose polymerase (PARP) inhibitors, AstraZeneca’s Lynparza (olaparib), GSK’s Zejula (niraparib) and Clovis Oncology’s Rubraca (rucaparib), were recently introduced to market, and these four targeted therapies collectively began to transform the treatment paradigm for ovarian cancer.

The ovarian cancer market in the 7 major markets (7MM: US, France, Germany, Italy, Spain, UK, Japan) is expected to experience massive growth between 2018 and 2018. The main drivers of growth will be label expansions, which will broaden patient eligibility for branded agents, provide more therapeutic options for maintenance settings, and bring novel combinations of branded agents and pipeline agents into the treatment paradigm. GlobalData expects the launch of nine pipeline agents throughout the forecast period, which will further add to growth, including five checkpoint inhibitors, a small molecule inhibitor of vascular endothelial growth factor receptor (VEGF-R), a new PARP inhibitor, a folate receptor-targeting antibody drug conjugate, and a viral-based gene therapy prod.

Key Highlights

Double-digit CAGR is expected in the ovarian cancer market from 2018 to 2028. The main driver of the growth of the ovarian cancer market will be adoption of maintenance therapy across the 7MM, PARP inhibitor uptake in the first-line setting, launch of new pipeline agents, and increased screening rates for genetic markers. Label expansions to broaden patient eligibility and the emergence of novel combinations of therapeutic agents will define the market over the forecast period. Market growth will be stalled due to generic and biosimilar erosion, with some of the key products for ovarian cancer, Avastin and Lynparza, losing protection over the forecast period. KOLs interviewed by GlobalData consider the binary categorization of ovarian cancer according to platinum-responsiveness outdated and highlight the need for more robust patient stratification according to genetic and histological biomarker status.

Key Questions Answered

How will the use of PARP inhibitors throughout various lines of treatment affect the treatment algorithm? The ovarian cancer market is characterized by a number of unmet needs. What are the main unmet needs in this market? Will the pipeline drugs under development fulfill these unmet needs? Among nine late-stage pipeline agents entering the ovarian cancer market, which will make a significant impact? Which of these drugs will have the highest peak sales, and why?

Scope

– Overview of ovarian cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management. – Annualized ovarian cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments and 11 lines of therapy, forecast from 2018 to 2028. – Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ovarian cancer therapeutics market. – Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for ovarian cancer. The most promising candidates in Phase III development are profiled. – Analysis of the current and future market competition in the global ovarian cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to – – Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving the global ovarian cancer market. – Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ovarian cancer market in the future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

[amanjadejablog]

Avastin (Ovarian Cancer) Market Sales, Segments, Capacity Outlook, Growth, Potential Applications and Analysis by 2024

“The Avastin (Ovarian Cancer)  market report is a complete research on the current state of the Avastin (Ovarian Cancer)  market with a focus on the regional market. This report presents the global Avastin (Ovarian Cancer)  market size (value, production, and consumption), splits the breakdown (data status 2013-2018 and forecast to ‘2024’), by manufacturers, region, type, and application. This study also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter’s Five Forces Analysis.

REPORT INCLUDES:

Data tables

An overview of the global market for Avastin (Ovarian Cancer)

Analyses of global market trends, with data from 2017, 2018, and projections of compound annual growth rates (CAGRs) through 2024

A look into background, history, development and evolution of Avastin (Ovarian Cancer) market

Detailed description about technologies, new developments and future of the Avastin (Ovarian Cancer)

Comprehensive analyses of the major players of the industry, including this Avastin (Ovarian Cancer) market research report

Get a FREE Sample PDF Report: https://www.marketgrowthinsight.com/sample/41233

The report also presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market.

The players mentioned in our report Roche Group(Genentech)

Global Avastin (Ovarian Cancer) Market: Product Segment Analysis 10 mg/kg 15 mg/kg Global Avastin (Ovarian Cancer) Market: Application Segment Analysis Cancer Treatment Wet age-related macular degeneration reatment Global Avastin (Ovarian Cancer) Market: Regional Segment Analysis USA Europe Japan China India South East Asia

Get Discount on this Report: https://www.marketgrowthinsight.com/discount/41233

The prime objective of this Avastin (Ovarian Cancer) research report is to define the size of the different segments and the geographies as well as to forecast the trends that are likely to gain traction in the following couple of years. This market research report has been designed to incorporate both the qualitative and quantitative aspects of the industry within each of the regions.

The scope of this report centers on key market analyses, market drivers & challenges, and competitive analysis & trends. Research report examines each market and its applications, regulatory scenario, technological innovations, Avastin (Ovarian Cancer) market projections, market sizes, and shares. Moreover, the Avastin (Ovarian Cancer) market report examines the most recent trends, pipeline products and developments in the Avastin (Ovarian Cancer)  market. Complete profiles of leading organizations in the market are also mentioned in this report.

In the end, It includes the methodical description of the various factors such as the market growth and a detailed information about the different company’s revenue, growth, technological developments, production, and the various other strategic developments.

REASONS TO BUY

Obtain the most up to date information available on active, planned and announced Avastin (Ovarian Cancer) in Specific Region

Identify growth segments and opportunities in the industry

Facilitate decision making on the basis of strong historic and outlook of capacity data

Assess key Avastin (Ovarian Cancer) data of your competitors.

This report is intended to enlighten manufacturers, product suppliers, providers, and suppliers. The intended audience also includes hospital system CEOs, provider groups, payer groups and investment firms working in the sector.

Purchase Avastin (Ovarian Cancer) Market Research Report: https://www.marketgrowthinsight.com/checkout/41233

Thus, the Avastin (Ovarian Cancer)  Market Report serves as a valuable material for all industry competitors and individuals having a keen interest in Avastin (Ovarian Cancer)  Market study.

About us : Market Growth Insight, is a one stop solution for market research reports in various business categories. We are serving 100+ clients with 10000+ diverse industry reports and our reports are developed to simplify strategic decision making, on the basis of comprehensive and in-depth significant information, established through wide ranging analysis and latest industry trends. Contact us : 502, Sai Radhe, Kenedy Road, Behind Hotel Sheraton Grand, Near Pune Station, Pune-411001, sales@marketgrowthinsight.com +1 347 767 5477

Connect With Us : Twitter | Linkedin | Facebook | Google+

  from WordPress https://ift.tt/319b3eq via IFTTT

[expertofmarketinsights-blog]

Ovarian Cancer Drugs Market To Witness Robust Expansion By 2026

Ovarian cancer is one of the most dreadful type of cancer widely found in women. In this cancer, abnormal cells growth is experienced in the ovaries, which has potential to invade or adversely affect other body parts such as abdomen layers, lining of the bowel and bladder, lymph nodes, and liver. Initial stages of ovarian cancer are associated with few vague symptoms, which further manifest as the cancer grows. These symptoms include inflating, pelvic ache, abdominal puffiness, and loss of appetite.

Request For Sample Copy of This Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/164

Ovarian cancer is a relatively rare cancer as compared to other types, though risk is higher among women who have ovulated more over their lifetime, which can also include females who have never borne a child and those who began ovulating at a very young age. According to American Cancer Society, around 10% of ovarian cancer cases are related to inherited genetic risk. Women with mutations in BRCA1 or BRCA2 genes have 50% chance of developing breast or ovarian cancer. Ovarian carcinoma, is the most common ovarian cancer that accounts for 95% of cases, globally.

Ovarian cancer drugs market supported by growing aging population in the U.S. and U.K.

Rising number of ovarian cancer cases recorded over the recent past, is creating a highly conducive environment for growth of the ovarian cancer drugs market. According to American Cancer Society, in 2016, around 22,280 new cases of ovarian cancer were diagnosed, leading to 14,240 deaths in the U.S. According to the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute data, an increase in all new cancer cases is recorded, with ovarian cancer accounting for 1.3% of the incidence rate, and 2.4% of all related deaths, in 2016. The number of new ovarian cancer cases account for 11.9 per 100,000 women, and the total deaths account for 7.5 per 100,000 women, annually.

According to World Cancer Research Fund International data on the basis of highest rate of ovarian cancer by country: Fiji, age standardized rate per 100,000 is 14.9, followed by Latvia and Bulgaria with age standardized rate per 100,000 being 14.2 and 14.0, respectively. The U.K. stands tenth, with age standardized rate per 100,000 pegged at 11.7. Around 58% of ovarian cancer cases are diagnosed in emerging economies, with the highest incidence rate recorded in Africa and Asia Pacific. In the U.K., around 46% of women diagnosed with ovarian cancer, survive for around five years or more following the onset of the disease.

Combinational drug approach, a novel approach in the ovarian cancer drugs market

Key players operating in the ovarian cancer drugs market include Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Novogen, Inc., Genentech Inc., Aetera Zenteris Inc., Boehringer Ingelheim GmbH, and F. Hoffman-La Roche Ltd. Major companies in this market are constantly working towards introducing innovative products and lowering production costs in order to enhance profitability. For instance, Roche’s blockbuster drug Avastin (bevacizumab) used in combination with carboplatin and paclitaxel is being used to treat ovarian cancer.

Current scenario in ovarian cancer drugs market: High prevalence of ovarian cancer among women over 60 years in the U.S. and U.K.

Regional segmentation of the global ovarian cancer drugs market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America accounts for the largest market share, mainly due to presence of major players and adoption of advanced medical technologies in countries such as the U.S. and Canada. According to American Cancer Society, an estimated 22,440 women would receive a new diagnosis of ovarian cancer and around 14,080 women will die from ovarian cancer in 2017 in the U.S. alone. Click to Read More On Ovarian Cancer Drugs Market.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

[myabhijitr]

Oncology Drugs Market Emerging Growth, Outlook and Opportunity Analysis, 2018–2026

Oncology Drugs Market is expected to have a highly positive outlook for the next five years 2018–2026 according to a recently released Oncology Drugs Market research report. The major takeaways in the report are product segment analysis, application segment analysis, regional segment analysis and data of the major Oncology Drugs Market players from around the world. The report presents an introductory as well as detailed information about the Oncology Drugs Market through a well-organized layout divided into easy to understand chapters.

Download PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2332

Increasing number of drugs are being approved for treating various types of cancer. According to U.S. FDA, around 16 new drugs were approved in 2017 for treatment of cancer. Moreover, by mid November 2018, eight more drugs were approved for cancer. Notable drug approvals from 2017 include,. Yescarta from Kite Pharmaceuticals that consist of the axicabtagene ciloleucel, for the treatment of relapsed or refractory large B-cell lymphomas (approved in October 2017), Kymriah (tisagenlecleucel) from Novartis for the treatment of refractory B-cell precursor acute lymphoblastic leukemia (approved in August 2017),. Imfinzi (durvalumab) from AstraZeneca for the treatment of advanced or metastatic urothelial carcinoma and stage III non-small cell lung cancer (approved in May 2017)

Cancer is one of the deadliest disease with less chance of survival as the disease progresses. International Agency for Research on Cancer published GLOBOCAN 2018 report, which estimates cancer incidence and mortality rate. This report focus on geographic variability of cancer incidence rate and mortality rate across 20 world regions. This report projected 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. Therefore, high prevalence of cancer is expected to be major factor for growth of the global oncology drugs market.

Lorbrena (lorlatinib) Pfizer, for the treatment of ALK-positive metastatic non-small cell lung cancer (approved in November 2018),. Increasing number of blockbuster drugs going off patent is expected to boost entry of biosimilars and generic versions of oncology drugs.

For instance, Avastin (bevacizumab), which is a Humanized Monoclonal Antibody product for Colorectal, lung, breast, glioblastoma, kidney, and ovarian cancer by Roche is going off patent by July 2019 in U.S.

Market Dynamics

Increasing drug approvals and robust pipeline for novel therapeutic agents are some of the key factors driving the oncology drugs market growth. For instance, in August 2017, Tisagenlecleucel (Kymriah), a drug developed by Novartis was approved by the U.S. Food and Drug Administration (FDA) for the treatment of pediatric and young adults with refractory or relapsed Acute Lymphoblastic Leukemia (ALL).

Moreover, increasing prevalence of various types of cancer is also fueling the oncology drugs market growth. For instance, according to a report by National Cancer Institute, 2016, around 16.8 million new cases of cancer are diagnosed in the U.S. every year, with around 595,690 deaths from the disease and the number of people with cancer is expected to increase to 19 million by 2024.

Major players operating in the global oncology drugs market include, Hoffmann-La Roche AG, Novartis International AG, Celgene Corporation, Johnson & Johnson, Bristol-Myers Squibb, Pfizer Inc., Merck & Co., Eli Lilly and Company, AbbVie, Inc., AstraZeneca plc., Bayer AG, and Amgen Inc.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2332

Detailed Segmentation:

Global Oncology Drugs Market, By Drug Type: Cytotoxic Drugs, Alkylating Agents, Antimetabolites, Others, Targeted Drugs, Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Others,. Hormonal Drugs, Ovarian Function Blockers, Estrogen Production Blockers, Estrogen’s Effect Blockers, Selective Estrogen Receptor Modulators (SERMs), Others,. Global Oncology Drugs Market, By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Blood Cancer, Bladder Cancer, Others,. Global Oncology Drugs Market, By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies,.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com

[azveille]

New insight into a struggling AstraZeneca anti-VEGF drug could expand its use in cancer

AstraZeneca’s experimental cancer drug cediranib was originally developed to inhibit VEGF, a protein that prompts the growth of the blood vessels tumors need to survive. But in clinical trials it hasn’t proven to be all that effective, failing to stack up to Roche’s anti-VEGF blockbuster Avastin.

But now, Yale University researchers have discovered that cediranib has a second function that could improve its prospects for treating cancer. In addition to blocking VEGF, it prevents cancer cells from being able to repair their DNA, causing them to die and promoting tumor shrinkage.

In so doing, cediranib makes tumors more likely to respond to drugs that directly inhibit the DNA repair enzyme PARP, including AstraZeneca’s Lynparza. The Yale team published its findings in the journal Science Translational Medicine.

"There is a lot of interest in the cancer field in developing DNA repair inhibitors because they will greatly help treatments, like radiotherapy and chemotherapy, that aim to destroy DNA in cancer cells," said senior author Peter Glazer, M.D., professor and chair of the department of therapeutic radiology at Yale Cancer Center, in a statement

Lynparza was initially approved to treat ovarian cancer marked by mutations in BRCA genes. But in a recent phase 2 trial, a combination of the drug with cediranib was effective in non-BRCA-mutated ovarian cancer, leading Glazer and his team on a quest to figure out exactly how the VEGF inhibitor was working.

Stunting the growth of blood vessels to tumors can lead to a depletion of oxygen, which in turn can make it more difficult for cells to repair their DNA. But the Yale researchers discovered in laboratory studies that cediranib actually has a much more direct effect on cancer cells.

It turns out the drug blocks DNA repair by disrupting a process called homology-directed repair. Cediranib breaks up that process by blocking platelet-derived growth factor receptor, which is essential to cell growth. That seems to make cancer cells more sensitive to PARP inhibitors.

AstraZeneca stopped developing cediranib as a monotherapy in 2016 but continued testing it with Lynparza in ovarian cancer and is now predicting an FDA filing for the combo in 2020.

Lynparza, meanwhile, remains an important growth driver for AstraZeneca. The drug’s sales nearly doubled in 2018 to $647 million as it claimed more prescriptions than other PARP inhibitors on the market.

The oncology research community continues to explore the use of PARP inhibitors in other cancers. Last year, a Yale group reported that the drugs may be useful in treating two rare inherited cancers, and U.K. researchers have been exploring Lynparza’s potential in treating glioblastoma

As for the Lynparza-cediranib combo, Glazer is optimistic that the potential of disrupting DNA repair from two different angles will prove to be valuable, and not just in ovarian cancer. "The goal now is to investigate how we can broaden the potential of this synthetic lethality to other cancer types," Glazer said.

[healthcaretrends-blog]

Oncology Drugs Market Product Opportunity, Industry Summary, Constraints

The global Oncology Drugs Market size is estimated to be valued at US$ 77.3 billion in 2018 and is expected to witness a CAGR of 12.3% over the forecast period (2018 – 2026).

Cancer is a class of chronic disease that is characterized by uncontrolled growth of cells. The most common cancer types are breast cancer, lung cancer, colorectal cancer, uterine cancer, and thyroid cancer. The three main types of drugs used for cancer, based on their mechanism of action, are cytotoxic drugs, targeted drugs, and hormonal drugs. Oncology drugs market has witnessed tremendous growth in the recent past, owing to increasing drug approvals and emergence of biosimilar products for cancer treatment. Furthermore, increasing healthcare expenditure for cancer has led to growing research and development activities for developing new cancer drugs that are highly effective and with least side-effects.

Key companies in the oncology drugs market are focused on targeting cancer treatment based on personalized medicines. According to Tufts Center for the Study of Drug Development (CSDD), 2015 report, 73% of the cancer medicines in the development have potential to be personalized medicine. Several researches are focused on targeting cancer at molecular level to offer new cancer treatments. According to an article published in The Biopharmaceutical Pipeline, 2013, new molecular entity for cancer treatment holds 80% share in the total pipeline products for cancer treatment. According to same source, the total number of potential first-in-class projects for cancer are 4,358 out of total 5,473 cancer projects.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/2332

However, several blockbuster oncology drugs are expected to lose their patent during 2018-2020, which in turn is expected to hamper the market growth during the forecast period. For instance, Roche’s Avastin, which is a humanized monoclonal antibody for the indication of colorectal, lung, breast, glioblastoma, kidney, and ovarian cancer is expected to lose its patent in July 2019 in the U.S. and in January 2022 in Europe. Some of the other drugs that are under patent expiration include, Bristol-Myers Squibb and Eli Lilly and Company’s Erbitux (cetuximab) by 2018; Roche’s Herceptin (trastuzumab) by 2019 and MabThera (Rituximab) by 2018; and Sanofi’s Zaltrap by 2020.

Presence of key market players and increasing drug approvals are attributing to the highest share of North America market in the global oncology drugs market

Regional oncology drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America oncology drugs market holds dominant position in the global oncology drugs market. Advanced medical treatment options available for cancer in economies such as the U.S. and increasing survival rate are key factors driving the market growth. For instance, according to the American Association for Cancer Research’s 2015 report, the number of survivors suffering from cancer increased from 9.8 million in 2001 to 14.5 million in 2014, owing to increasing adoption of better medical facilities. Moreover, increasing R&D activities by local players such as Spark Therapeutics, Inc. and Kite Pharmaceuticals and increasing product approvals by the U.S. FDA are boosting the market growth in North America.

Furthermore, Asia Pacific is expected to witness significant growth in the market, owing to increasing focus of international player on strategies such as mergers and acquisitions. For instance, in February 2018, Merck acquired Viralytics Limited, a Sydney-based immune-oncology drug developer, to strengthen its immune-oncology drug pipeline. Moreover, increasing prevalence of various types of cancer in economies such as India and China is also expected to propel growth of the market. For instance, according to the American Cancer Society, 2015, around 4.3 million new cancer cases and over 2.8 million cancer deaths were recorded in China, with lung cancer being the most common and the leading cause of cancer deaths.

Click To Reading More On Oncology Drugs Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

[pragya1-blog]

Solid Tumor Market : Segmentation, Opportunities, Trends & Future Scope to 2023

Solid tumors are formed due to aggregation of a group of abnormal tissues that do not comprise of any cyst or liquid areas within. Solid tumors can be of both types, i.e. benign (non-cancerous) as well as malignant (cancerous) in nature. Solid tumors majorly comprise of lymphomas, carcinomas, sarcomas and melanomas; whereas, all forms of leukemias usually do not cause solid tumor formation. The treatment of these solid tumors is a complex task and it requires coordinated actions of many healthcare professionals, such as, radiologists, surgeons, oncologists, radiation specialists, nurses and other professionals. Hence, most of the solid tumors are treated via radiotherapy, chemotherapy and/or surgery. However, at present, surgery is the most preferred choice of treatment for cancerous solid tumors. Chemotherapy is often utilized along with other modes of solid tumor treatment i.e. radiation and/or surgery. Several chemotherapeutic drugs are available along with a ripe pipeline of drugs that will soon be commercialized in the global market. Solid tumor market can be classified into five major segments, based on the site of origin, namely, prostrate cancer, ovarian cancer, bladder cancer, pancreatic cancer and other cancers.

Obtain Report Details @

https://www.transparencymarketresearch.com/solid-tumor-market.html

Some of the major driving factors for the growth of this market include increasing incidences of several cases of solid tumors, rising prevalence of different forms of metastatic cancers, increasing demand for highly effective chemotherapeutic agents and ripe pipeline of drugs which is available in the global market. According to World Health Organization (WHO), approximately 8.2 million people died due to different types of cancers worldwide in 2012. Among them lung, colorectal, breast and liver cancers were among the leading causes of cancer deaths. Most common forms of solid tumors include brain tumors (medulloblastoma and glioma) and neuroblastoma; other less common solid tumors include rhabdomyosarcoma and osteosarcoma.

Request Report Brochure @

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8209

Some of the major drugs that available in the global market are Avastin (bevacizumab), Afinitor (everolimus), Jevtana (cabazitaxel), Sutent (sunitinib), Tarceva (erlotinib), Taxotere (docetaxel), Zytiga (abiraterone acetate), Carboplatin, Cisplatin, Doxorubicin, Gemcitabine and Paclitaxel among others. Also, major promising drugs that are in different stages of clinical trials include Abraxane (albumin-bound paclitaxel), AMG 386 (trebananib), Votrient (pazopanib) and Xtandi (enzalutamide) among others. These drugs will soon be commercialized in the global market, which will further boost this market in future.

Enquiry for Discount on this Report @

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=8209

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research State Tower, 90 State Street, Suite 700 Albany, NY 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: www.transparencymarketresearch.com